Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
TTS 2.45 −2.0% FCI 0.400 −9.1% GR 0.075 +0.0% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% S 0.155 +29.2% DEX 0.390 +1.3% TTS 2.45 −2.0% FCI 0.400 −9.1% GR 0.075 +0.0% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% S 0.155 +29.2% DEX 0.390 +1.3%
M&A / Property Routine +

The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

Precision Peptide Solidifies MMA Partnership While Regulatory Clock Ticks Toward July Review

By The Northwire Desk — AI Analysis May 21, 2026 · 07:31 BPC · 0.445 The Precision Peptide Company Inc.
Executive Summary
  • The most recent release (May 21, 2026) confirms and expands on the exclusive strategic marketing partnership with Mixed Martial Arts Group Limited (MMA.INC) announced on May 12.
  • Key terms include a tiered revenue share: 50/50 in Year 1, shifting to 75/25 in Precision's favor from Month 13 onwards.
  • The agreement requires no upfront capital investment and includes a 12-month "tail period" for revenue sharing post-termination.
  • MMA.INC ecosystem reach is detailed: over 5 million social media followers, 800+ verified gyms across 16 countries, and key platform assets like TrainAlta and MixedMartialArts.com.
  • Adjacent news (May 19) confirms the lead product (BPC-157 transdermal patch) achieved 95.5% purity in independent lab testing, clearing industry benchmarks for commercial launch readiness.
  • Regulatory context notes FDA Pharmacy Compounding Advisory Committee evaluation scheduled for July 23, 2026.
Material Impact
  • The May 21 announcement is a confirmation of the material positive news released on May 12; it does not introduce new financial terms or unexpected strategic shifts that would alter the valuation thesis established days prior.
  • While the partnership provides access to a large consumer base, revenue recognition depends entirely on execution and conversion rates within MMA.INC's ecosystem, which remains unquantified in this release.
  • The 95.5% purity result (May 19) is positive but routine for a company approaching commercial launch; it validates the product quality but does not guarantee sales volume.
  • Given the price action from May 12 ($0.50) to May 20 ($0.44), the market has already digested the initial partnership news, suggesting this update is incremental rather than transformative.
  • The lack of upfront capital requirement reduces immediate cash burn risk but increases reliance on partner marketing effectiveness for revenue generation.
BPC · Price
Company Overview
  • The Precision Peptide Company focuses on peptide therapeutics for wellness and recovery, specifically targeting consumer-friendly delivery methods.
  • Flagship Project: BPC-157 transdermal patch (needle-free), designed to eliminate injections and reconstitution barriers.
  • Secondary Pipeline: Immune Defense Patch (Thymosin Alpha-1) under development on the same platform.
  • Manufacturing: Products are U.S.-manufactured with third-party testing for FDA compliance, distinguishing it from unregulated compounding markets.
Read the original news release →

More from The Precision Peptide Company Inc.

Jun 23, 2026 · 07:31

Compliance milestones unlock e-commerce scaling, but regulatory clarity remains the true catalyst.

Other Jun 11, 2026 · 17:01

Pre-revenue peptide developer secures at-market capital to fund U.S. commercial rollout amid regulatory tailwinds.

Financings Jun 09, 2026 · 07:31

Building compliant U.S. telehealth and compounding infrastructure ahead of pivotal July FDA PCAC review.

M&A / Property Jun 02, 2026 · 07:01

The Precision Peptide Company Inc.

Financings May 26, 2026 · 07:31

Precision Peptide Advances Commercial Launch with MMA Partnership Backing

Other May 21, 2026 · 09:00

McGregor and Trump Jr. muscle into peptide marketing pact, but needle-free patch launch remains the real prize

Financings